ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
N, S Co-Doped Carbon Quantum Dots-Riboflavin Composite Photosensitizers for Enhanced Iontophoresis-Assisted Corneal Cross-Linking.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Iontophoresis-assisted corneal cross-linking (I-CXL) is an emerging transepithelial technique for treating keratoconus. I-CXL employs a small electric current to enhance the corneal penetration of riboflavin 5'-phosphate sodium (RF), avoiding the de-epithelialization side effects associated with conventional CXL (C-CXL). However, I-CXL is less effective than C-CXL due to insufficient RF surface charge hindering iontophoresis response and absorption efficiency, as well as inadequate reactive oxygen species (ROS) generation in the corneal stroma. This work reports the development of an innovative composite photosensitizer (NS-CQDs-RF), utilizing N, S co-doped carbon quantum dots (NS-CQDs) as nanocarriers, to overcome the bottlenecks facing I-CXL. Experimental results show that the as-synthesized NS-CQDs-RF composites exhibit a remarkable electric field response, enhanced RF corneal permeability, high ROS production efficiency, and excellent biocompatibility. Notably, I-CXL incorporating NS-CQDs-RF significantly improves corneal biomechanical stability, outperforming C-CXL while reducing total UVA irradiation energy without compromising efficacy. Density Functional Theory (DFT) calculations reveal that the optimized electronic structure and favorable energetics between NS-CQDs and RF drive efficient charge transfer, amplifying ROS generation. These findings highlight the superiority of the NS-CQDs-RF composite photosensitizers in I-CXL, offering a novel strategy for future keratoconus treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.